GlassScriptPhysician profile
Fernando Jerves Coello
NPI 1700413093
$1,731.44
in general payments reported to CMS, 2019-2025
21 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $269 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.45 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $282.60 | 2025 | Enhertu, Vanflyta, Datroway |
| Janssen Biotech, INC. | $199.08 | 2025 | Rybrevant, Carvykti, Talvey |
| Adaptive Biotechnologies Corporation | $187.67 | 2025 | Clonoseq |
| Genzyme Corporation | $162.65 | 2024-2025 | |
| Caris Mpi, INC. | $135.10 | 2025 | Mi Cancer Seek |
| Kite Pharma, INC. | $126.37 | 2025 | Yescarta |
| Secura Bio, INC. | $122.42 | 2025 | Copiktra |
| Merck Sharp & Dohme LLC | $111.88 | 2024-2025 | Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $98.39 | 2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $42.01 | 2025 | Enhertu, Lynparza |
| Genmab U.S., INC. | $39.57 | 2025 | Epkinly |
| Incyte Corporation | $33.25 | 2024-2025 | Jakafi, Jakafi |
| Tempus Ai, INC | $29.98 | 2024 | |
| Abbvie INC. | $27.88 | 2025 | |
| Amgen INC. | $23.90 | 2024 | Blincyto |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $19.43 | 2025 | Libtayo |
| Agios Pharmaceuticals, INC. | $18.82 | 2025 | Pyrukynd |
| Celgene Corporation | $18.00 | 2025 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $17.88 | 2025 | |
| Lilly USA, LLC | $17.60 | 2024 | Jaypirca |
| Geron Corporation | $16.96 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Jerves Coello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.